Published within
|«
«
|
...
|
5
|
6
|
7
|
8
|
9
|
10
|
11
|
12
|
13
|
...
|
»
»|
| Type |
Product title / description
|
Pub
|
Price |
Expert View
|
Bringing improved patient compliance, depot formulations tackle a crucial unmet need in schizophrenia and the FDA approval of Invega Sustenna and Zyprexa Relprevv represent important steps to improve the transparency of compliance. At this year's American Psychiatric Association meeting, both Johnson & Johnson and Eli Lilly presented data of these depots' long-term efficacy and safety.
Published By Datamonitor
|
10 Jun 2010 |
|
Expert View
|
Key themes presented in the field of major depressive disorder at this year's American Psychiatric Association annual meeting included treatment-resistant depression, transcranial magnetic stimulation and adjunctive use of antipsychotics. While no new clinical trial data were presented, those that were provide an interesting insight into the strategies of a number of major pharmaceutical players.
Published By Datamonitor
|
10 Jun 2010 |
|
Expert View
|
Datamonitor recently attended the 164th Annual Meeting of the American Psychiatric Association in Honolulu, Hawaii, which ran over May 14-18, 2011. Of particular interest were the promising data presented for several agents in late-stage development for treatment-resistant depression. Below are the highlights of the conference's coverage of developmental depression drugs.
Published By Datamonitor
|
27 May 2011 |
|
Expert View
|
With patents of several psychiatric drugs set to expire in the US and EU over 2011-12, key players are increasingly seeking to expand their geographical reach to growth markets in an attempt to extend revenue streams. In apparent recognition of this trend, the 164th Annual Meeting of the American Psychiatric Association included a forum dedicated to Chinese psychiatric services and research.
Published By Datamonitor
|
27 May 2011 |
|
Expert View
|
Adjunctive therapies in depression, schizophrenia, and attention deficit hyperactivity disorder were key themes at the 164th American Psychiatric Association Annual Meeting. However, three conditions characterized by a high level of unmet need did not go overlooked: bipolar disorders, substance dependence, and autism.
Published By Datamonitor
|
27 May 2011 |
|
Expert View
|
Datamonitor recently attended the 164th Annual Meeting of the American Psychiatric Association in Honolulu, Hawaii, which ran over May 14-18, 2011. The focus in schizophrenia was on long-term data for new market entrants and treatment adherence, with limited new clinical trial data for pipeline candidates.
Published By Datamonitor
|
26 May 2011 |
|
Expert View
|
Datamonitor attended the 164th Annual Meeting of the American Psychiatric Association in Honolulu, Hawaii, which ran over May 14-18, 2011. In attention deficit hyperactivity disorder, the promotion of recent market entrants Intuniv and Kapvay took precedence, with presentations of post-marketing long-term clinical data.
Published By Datamonitor
|
26 May 2011 |
|
Expert View
|
Forest and Gedeon's cariprazine is a pharmacologically unique atypical antipsychotic in Phase III development for both schizophrenia and bipolar mania. Data presented at APA 2012 hint that while cariprazine appears to be effective in both indications, its tolerability and failure to address the broader bipolar depression patient population will hinder uptake.
Published By Datamonitor
|
15 May 2012 |
|
Expert View
|
The DSM-5, the latest edition of the gold-standard diagnostic guidelines in psychiatry throughout the world, is due to be unveiled in May 2013. Given the huge size of the psychiatry drug market, any changes made to the diagnoses of conditions such as depression, bipolar disorders, and schizophrenia - however slight - will be of great interest to the pharmaceutical industry.
Published By Datamonitor
|
15 May 2012 |
|
Expert View
|
Pooled data released at the APA 2012 suggest that Forest's Viibryd combines a fast onset of antidepressant activity with a favorable side-effect profile, satisfying two important unmet needs in depression pharmacotherapy. Conversely, results from the Phase III program for levomilnacipran are less impressive, suggesting that the drug offers little benefit over other drugs in its class.
Published By Datamonitor
|
15 May 2012 |
|
|«
«
|
...
|
5
|
6
|
7
|
8
|
9
|
10
|
11
|
12
|
13
|
...
|
»
»|
No help is available.
Reports and briefs contain analyst driven analysis and opinion covering a specific market or issue.
Business Insight reports are an objective source of data, analysis and market insight
Insight for technology vendors into customer trends and pain points from key business decision makers.
Butler Group's thought leadership, opinion, with end user case studies and product profiles for key vendors.
Butler Group's vendor ranking and assessment model groups vendors into Outperform, Perform, and Under-perform categories.
Butler Group's thought leadership, opinion, and best practice with technology audits, product comparisons and rankings.
Opinion and market commentary from Datamonitor's industry experts.
Company profiles deliver detailed insight into how companies are organized and function with SWOT analysis.
Company reports provide detailed company evaluations.
Opinion and market commentary from Datamonitor's industry experts.
Company reports provide detailed company evaluations.
Opinion and market commentary from Datamonitor's industry experts.
Opinion and market commentary from Datamonitor's industry experts.
Track industry events, markets, products, customers, prospects, competitors and partners
Country profiles presenting easy-to-digest summaries and standardized data.
Databooks use charts and tables to provide a data-centric view of a particular market or category
Opinion and market commentary from Datamonitor's industry experts.
Comprehensive category data, including market value, volume, segmentation and share, with analysis.
Industry profiles provide standardized market data (including size & segmentation) and competitive analysis.
Market sizing and forecast data for a market or sector delivered in spreadsheet format.
Track industry events, markets, products, customers, prospects, competitors and partners
Ovum's research addresses the commercial impact of technology and market changes in telecoms, software and IT services.
Ovum's research addresses the commercial impact of technology and market changes in telecoms, software and IT services.
Ovum's research addresses the commercial impact of technology and market changes in telecoms, software and IT services.
Ovum's research addresses the commercial impact of technology and market changes in telecoms, software and IT services.
Ovum's research addresses the commercial impact of technology and market changes in telecoms, software and IT services.
Ovum's research addresses the commercial impact of technology and market changes in telecoms, software and IT services.
Ovum's research addresses the commercial impact of technology and market changes in telecoms, software and IT services.
Ovum's research addresses the commercial impact of technology and market changes in telecoms, software and IT services.
Ovum's research addresses the commercial impact of technology and market changes in telecoms, software and IT services.
Reports and briefs contain analyst driven analysis and opinion covering a specific market or issue.
Opinion and market commentary from Datamonitor's industry experts.
Insight for technology vendors into customer trends and pain points from key business decision makers.
Business information covering a specific market or issue.